Abivax's Acquisition Uncertainty Continues Amid Biotech Boom
By Editor • September 3, 2026 • 1 min read
Despite soaring biotech mergers and acquisitions, French pharmaceutical company Abivax remains independent, leaving investors anxious.
With expectations of a $20 billion buyout circulating for nine months, the lack of progress has sparked frustration among shareholders.
The mystery surrounding negotiations with potential Big Pharma buyers only adds to the speculation, with some attributing the delay to the traditional August slowdown in France.
Source: www.statnews.com
